0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Cancer CDK Inhibitors Market Research Report 2024
Published Date: January 2024
|
Report Code: QYRE-Auto-33A5945
Home | Market Reports | Health| Health Conditions| Cancer
Global Cancer CDK Inhibitors Market Insights and Forecast to 2028
BUY CHAPTERS

Global Cancer CDK Inhibitors Market Research Report 2024

Code: QYRE-Auto-33A5945
Report
January 2024
Pages:62
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Cancer CDK Inhibitors Market

A CDK (cyclin-dependent kinase) inhibitor is any chemical that inhibits the function of CDKs. They are used to treat cancers by preventing overproliferation of cancer cells. The US FDA approved the first drug of this type, palbociclib (Ibrance), a CDK4/6 inhibitor, in February 2015, for use in postmenopausal women with breast cancer that is estrogen receptor positive and HER2 negative. Several compounds are in clinical trials.
The global Cancer CDK Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
These inhibitors specifically inhibit CDK4/6 and show limited toxicity to normal cells. There are three FDA-approved CDK4/6 inhibitors and they are Palbociclib produced by Pfizer, Ribociclib produced by Novartis and Abemaciclib produced by Eli Lilly.
This report aims to provide a comprehensive presentation of the global market for Cancer CDK Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer CDK Inhibitors.

Report Scope

The Cancer CDK Inhibitors market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer CDK Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer CDK Inhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Cancer CDK Inhibitors Market Report

Report Metric Details
Report Name Cancer CDK Inhibitors Market
Segment by Type
  • CDK4/6
  • CDK2
Segment by Application
  • Hospitals
  • Clinics
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Pfizer, Novartis, Eli-Lilly
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Cancer CDK Inhibitors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Cancer CDK Inhibitors Market report?

Ans: The main players in the Cancer CDK Inhibitors Market are Pfizer, Novartis, Eli-Lilly

What are the Application segmentation covered in the Cancer CDK Inhibitors Market report?

Ans: The Applications covered in the Cancer CDK Inhibitors Market report are Hospitals, Clinics

What are the Type segmentation covered in the Cancer CDK Inhibitors Market report?

Ans: The Types covered in the Cancer CDK Inhibitors Market report are CDK4/6, CDK2

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer CDK Inhibitors Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CDK4/6
1.2.3 CDK2
1.3 Market by Application
1.3.1 Global Cancer CDK Inhibitors Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer CDK Inhibitors Market Perspective (2019-2030)
2.2 Cancer CDK Inhibitors Growth Trends by Region
2.2.1 Global Cancer CDK Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cancer CDK Inhibitors Historic Market Size by Region (2019-2024)
2.2.3 Cancer CDK Inhibitors Forecasted Market Size by Region (2025-2030)
2.3 Cancer CDK Inhibitors Market Dynamics
2.3.1 Cancer CDK Inhibitors Industry Trends
2.3.2 Cancer CDK Inhibitors Market Drivers
2.3.3 Cancer CDK Inhibitors Market Challenges
2.3.4 Cancer CDK Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer CDK Inhibitors Players by Revenue
3.1.1 Global Top Cancer CDK Inhibitors Players by Revenue (2019-2024)
3.1.2 Global Cancer CDK Inhibitors Revenue Market Share by Players (2019-2024)
3.2 Global Cancer CDK Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer CDK Inhibitors Revenue
3.4 Global Cancer CDK Inhibitors Market Concentration Ratio
3.4.1 Global Cancer CDK Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer CDK Inhibitors Revenue in 2023
3.5 Cancer CDK Inhibitors Key Players Head office and Area Served
3.6 Key Players Cancer CDK Inhibitors Product Solution and Service
3.7 Date of Enter into Cancer CDK Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer CDK Inhibitors Breakdown Data by Type
4.1 Global Cancer CDK Inhibitors Historic Market Size by Type (2019-2024)
4.2 Global Cancer CDK Inhibitors Forecasted Market Size by Type (2025-2030)
5 Cancer CDK Inhibitors Breakdown Data by Application
5.1 Global Cancer CDK Inhibitors Historic Market Size by Application (2019-2024)
5.2 Global Cancer CDK Inhibitors Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cancer CDK Inhibitors Market Size (2019-2030)
6.2 North America Cancer CDK Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cancer CDK Inhibitors Market Size by Country (2019-2024)
6.4 North America Cancer CDK Inhibitors Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer CDK Inhibitors Market Size (2019-2030)
7.2 Europe Cancer CDK Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cancer CDK Inhibitors Market Size by Country (2019-2024)
7.4 Europe Cancer CDK Inhibitors Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer CDK Inhibitors Market Size (2019-2030)
8.2 Asia-Pacific Cancer CDK Inhibitors Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2019-2024)
8.4 Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer CDK Inhibitors Market Size (2019-2030)
9.2 Latin America Cancer CDK Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cancer CDK Inhibitors Market Size by Country (2019-2024)
9.4 Latin America Cancer CDK Inhibitors Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer CDK Inhibitors Market Size (2019-2030)
10.2 Middle East & Africa Cancer CDK Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2019-2024)
10.4 Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Cancer CDK Inhibitors Introduction
11.1.4 Pfizer Revenue in Cancer CDK Inhibitors Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Cancer CDK Inhibitors Introduction
11.2.4 Novartis Revenue in Cancer CDK Inhibitors Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Eli-Lilly
11.3.1 Eli-Lilly Company Detail
11.3.2 Eli-Lilly Business Overview
11.3.3 Eli-Lilly Cancer CDK Inhibitors Introduction
11.3.4 Eli-Lilly Revenue in Cancer CDK Inhibitors Business (2019-2024)
11.3.5 Eli-Lilly Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Cancer CDK Inhibitors Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of CDK4/6
    Table 3. Key Players of CDK2
    Table 4. Global Cancer CDK Inhibitors Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 5. Global Cancer CDK Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 6. Global Cancer CDK Inhibitors Market Size by Region (2019-2024) & (US$ Million)
    Table 7. Global Cancer CDK Inhibitors Market Share by Region (2019-2024)
    Table 8. Global Cancer CDK Inhibitors Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 9. Global Cancer CDK Inhibitors Market Share by Region (2025-2030)
    Table 10. Cancer CDK Inhibitors Market Trends
    Table 11. Cancer CDK Inhibitors Market Drivers
    Table 12. Cancer CDK Inhibitors Market Challenges
    Table 13. Cancer CDK Inhibitors Market Restraints
    Table 14. Global Cancer CDK Inhibitors Revenue by Players (2019-2024) & (US$ Million)
    Table 15. Global Cancer CDK Inhibitors Market Share by Players (2019-2024)
    Table 16. Global Top Cancer CDK Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer CDK Inhibitors as of 2023)
    Table 17. Ranking of Global Top Cancer CDK Inhibitors Companies by Revenue (US$ Million) in 2023
    Table 18. Global 5 Largest Players Market Share by Cancer CDK Inhibitors Revenue (CR5 and HHI) & (2019-2024)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Cancer CDK Inhibitors Product Solution and Service
    Table 21. Date of Enter into Cancer CDK Inhibitors Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Cancer CDK Inhibitors Market Size by Type (2019-2024) & (US$ Million)
    Table 24. Global Cancer CDK Inhibitors Revenue Market Share by Type (2019-2024)
    Table 25. Global Cancer CDK Inhibitors Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 26. Global Cancer CDK Inhibitors Revenue Market Share by Type (2025-2030)
    Table 27. Global Cancer CDK Inhibitors Market Size by Application (2019-2024) & (US$ Million)
    Table 28. Global Cancer CDK Inhibitors Revenue Market Share by Application (2019-2024)
    Table 29. Global Cancer CDK Inhibitors Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 30. Global Cancer CDK Inhibitors Revenue Market Share by Application (2025-2030)
    Table 31. North America Cancer CDK Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 32. North America Cancer CDK Inhibitors Market Size by Country (2019-2024) & (US$ Million)
    Table 33. North America Cancer CDK Inhibitors Market Size by Country (2025-2030) & (US$ Million)
    Table 34. Europe Cancer CDK Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 35. Europe Cancer CDK Inhibitors Market Size by Country (2019-2024) & (US$ Million)
    Table 36. Europe Cancer CDK Inhibitors Market Size by Country (2025-2030) & (US$ Million)
    Table 37. Asia-Pacific Cancer CDK Inhibitors Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 38. Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2019-2024) & (US$ Million)
    Table 39. Asia-Pacific Cancer CDK Inhibitors Market Size by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Cancer CDK Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 41. Latin America Cancer CDK Inhibitors Market Size by Country (2019-2024) & (US$ Million)
    Table 42. Latin America Cancer CDK Inhibitors Market Size by Country (2025-2030) & (US$ Million)
    Table 43. Middle East & Africa Cancer CDK Inhibitors Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Middle East & Africa Cancer CDK Inhibitors Market Size by Country (2025-2030) & (US$ Million)
    Table 46. Pfizer Company Detail
    Table 47. Pfizer Business Overview
    Table 48. Pfizer Cancer CDK Inhibitors Product
    Table 49. Pfizer Revenue in Cancer CDK Inhibitors Business (2019-2024) & (US$ Million)
    Table 50. Pfizer Recent Development
    Table 51. Novartis Company Detail
    Table 52. Novartis Business Overview
    Table 53. Novartis Cancer CDK Inhibitors Product
    Table 54. Novartis Revenue in Cancer CDK Inhibitors Business (2019-2024) & (US$ Million)
    Table 55. Novartis Recent Development
    Table 56. Eli-Lilly Company Detail
    Table 57. Eli-Lilly Business Overview
    Table 58. Eli-Lilly Cancer CDK Inhibitors Product
    Table 59. Eli-Lilly Revenue in Cancer CDK Inhibitors Business (2019-2024) & (US$ Million)
    Table 60. Eli-Lilly Recent Development
    Table 61. Research Programs/Design for This Report
    Table 62. Key Data Information from Secondary Sources
    Table 63. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Cancer CDK Inhibitors Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global Cancer CDK Inhibitors Market Share by Type: 2023 VS 2030
    Figure 3. CDK4/6 Features
    Figure 4. CDK2 Features
    Figure 5. Global Cancer CDK Inhibitors Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 6. Global Cancer CDK Inhibitors Market Share by Application: 2023 VS 2030
    Figure 7. Hospitals Case Studies
    Figure 8. Clinics Case Studies
    Figure 9. Cancer CDK Inhibitors Report Years Considered
    Figure 10. Global Cancer CDK Inhibitors Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 11. Global Cancer CDK Inhibitors Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 12. Global Cancer CDK Inhibitors Market Share by Region: 2023 VS 2030
    Figure 13. Global Cancer CDK Inhibitors Market Share by Players in 2023
    Figure 14. Global Top Cancer CDK Inhibitors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer CDK Inhibitors as of 2023)
    Figure 15. The Top 10 and 5 Players Market Share by Cancer CDK Inhibitors Revenue in 2023
    Figure 16. North America Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 17. North America Cancer CDK Inhibitors Market Share by Country (2019-2030)
    Figure 18. United States Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 19. Canada Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 20. Europe Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. Europe Cancer CDK Inhibitors Market Share by Country (2019-2030)
    Figure 22. Germany Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. France Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. U.K. Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. Italy Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Russia Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. Nordic Countries Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. Asia-Pacific Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Asia-Pacific Cancer CDK Inhibitors Market Share by Region (2019-2030)
    Figure 30. China Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Japan Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. South Korea Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Southeast Asia Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. India Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Australia Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. Latin America Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Latin America Cancer CDK Inhibitors Market Share by Country (2019-2030)
    Figure 38. Mexico Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. Brazil Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. Middle East & Africa Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. Middle East & Africa Cancer CDK Inhibitors Market Share by Country (2019-2030)
    Figure 42. Turkey Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Saudi Arabia Cancer CDK Inhibitors Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Pfizer Revenue Growth Rate in Cancer CDK Inhibitors Business (2019-2024)
    Figure 45. Novartis Revenue Growth Rate in Cancer CDK Inhibitors Business (2019-2024)
    Figure 46. Eli-Lilly Revenue Growth Rate in Cancer CDK Inhibitors Business (2019-2024)
    Figure 47. Bottom-up and Top-down Approaches for This Report
    Figure 48. Data Triangulation
    Figure 49. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Gene Therapy For Cancer Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-22G13317
Fri Feb 23 00:00:00 UTC 2024

Add to Cart

Global Cancer Biomarkers Detection Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-30Q5590
Fri Feb 23 00:00:00 UTC 2024

Add to Cart

Global Oncology Companion Diagnostic Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-14K8500
Fri Feb 23 00:00:00 UTC 2024

Add to Cart

Global Throat Cancer Treatment Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-8R8713
Fri Feb 23 00:00:00 UTC 2024

Add to Cart